$120.85$150.99
Prepare to embark on a sensory journey with the Bosco Apple, a fruit that transcends the ordinary and promises an unparalleled taste experience. These apples are nothing short of nature’s masterpiece, celebrated for their distinctive blend of flavors and their captivating visual allure.
Availability: In Stock
Subscribe to out newsletter today to receive latest news administrate cost effective for tactical data.
₹398
INTRODUCTION AFOGATRAN 150MG CAPSULE contains Dabigatran etexilate which belongs to the group of medicines called Anticoagulants. It is used to prevent stroke, systemic embolism and reduction of vascular mortality in adult patients with atrial fibrillation and venous thr...
AFOGATRAN 150MG CAPSULE contains Dabigatran etexilate which belongs to the group of medicines called Anticoagulants. It is used to prevent stroke, systemic embolism and reduction of vascular mortality in adult patients with atrial fibrillation and venous thromboembolic events in patients who have undergone orthopaedic surgery.
It is also used to treat acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE) and prevents recurrent deep vein thrombosis (DVT) and /or pulmonary embolism (PE). This medicine is also used in children to treat blood clots and to prevent blood clots from reoccurring.
Avoid taking AFOGATRAN 150MG CAPSULE, if you currently have bleeding disorders, organ disease of the body that increases the risk of serious bleeding such as stomach ulcer, injury or bleeding in the brain, severely reduced kidney or liver function.
Before taking AFOGATRAN 150MG CAPSULE, inform your doctor if you have increased bleeding risks such as s bone fracture, head injury or any injury requiring surgical treatment, lung or heart problems.
AFOGATRAN 150MG CAPSULE is not recommended for use in pregnant and breastfeeding women. Consult your doctor before taking AFOGATRAN 150MG CAPSULE.
Your doctor will prescribe the right dose depends on your child’s age body weight and disease condition. Consult your doctor before taking AFOGATRAN 150MG CAPSULE.
The most common side effects of taking AFOGATRAN 150MG CAPSULE are stomachache, indigestion, frequent loose or liquid bowel movements and or nausea. Consult your doctor if any of these above side effects gets worse.
It is used to:
AFOGATRAN 150MG CAPSULE works by blocking thrombin (blood central clotting agent) that results in the prevention of blood clots thereby preventing the occurrence of stroke, heart attack, deep vein thrombosis and pulmonary embolism.
Take AFOGATRAN 150MG CAPSULE as advised by your physician. Swallow AFOGATRAN 150MG CAPSULE with a glass of water and do not chew or crush the medicine. Your doctor will decide the correct dose and duration for you depending upon your age, body weight and disease condition.
Stop taking AFOGATRAN 150MG CAPSULE and contact your doctor if you experience any of the following side effects:
Dizziness:
Try to rest and relax and get enough sleep. Try to avoid driving or operating any tools or machines while you are feeling dizzy. Limit your consumption of alcohol, as it can aggravate your dizziness. Consult and inform your doctor if the symptom does not improve.
Nausea and Vomiting:
Try to take AFOGATRAN 150MG CAPSULE with or just after a meal or a snack. Stick to simple meals. Avoid eating rich or spicy food. Consult your doctor if the symptom gets worse.
Indigestion:
Try to have smaller and more frequent meals and eat slowly. Try to reduce consumption of tea, coffee, cola or alcohol and lose weight if you are obese. Consult and inform your doctor if the symptom does not improve.
AFOGATRAN 150MG CAPSULE is not recommended for use in pregnant women. Consult your doctor before taking AFOGATRAN 150MG CAPSULE.
AFOGATRAN 150MG CAPSULE is not recommended for use in breastfeeding women. Consult your doctor before taking AFOGATRAN 150MG CAPSULE.
AFOGATRAN 150MG CAPSULE has no known effects to affect the ability to drive or use machines. Consult your doctor before taking AFOGATRAN 150MG CAPSULE.
Avoid Consumption of alcohol while taking AFOGATRAN 150MG CAPSULE. Consult your doctor for advice.
AFOGATRAN 150MG CAPSULE is not recommended for use in patients with severely reduced kidney function. Consult your doctor before taking AFOGATRAN 150MG CAPSULE.
AFOGATRAN 150MG CAPSULE is not recommended for use in patients with severe liver disease or reduced liver function. Consult your doctor for advice before taking AFOGATRAN 150MG CAPSULE.
Do not take AFOGATRAN 150MG CAPSULE if you are allergic to Dabigatran etexilate or any of the other ingredients of this medicine.
AFOGATRAN 150MG CAPSULE should be used with caution in patients with lung problems such as pulmonary embolism (blood clot in lungs). Consult your doctor before taking AFOGATRAN 150MG CAPSULE.
AFOGATRAN 150MG CAPSULE is not recommended for use if you have received an artificial heart valve that requires permanent blood thinning. It should be used with caution in patients with heart problems such as heart attack, bacterial endocarditis (infection in the heart). Consult your doctor before taking AFOGATRAN 150MG CAPSULE.
AFOGATRAN 150MG CAPSULE is not recommended for use if you:
Before taking AFOGATRAN 150MG CAPSULE, inform your doctor if you:
Use in pediatrics:
AFOGATRAN 150MG CAPSULE is recommended for use in children and adolescents (from 8 to 18 years of age) to treat and reduce the risk of recurrence of blood clot disorder. Your doctor will prescribe the right dose depends on your child’s age, body weight and disease condition. Consult your doctor before taking AFOGATRAN 150MG CAPSULE.
Use in geriatrics:
AFOGATRAN 150MG CAPSULE is used with caution in elderly patients (aged 75 years or above). Consult your doctor before taking AFOGATRAN 150MG CAPSULE.
A. Drug-Drug Interactions:
Before taking AFOGATRAN 150MG CAPSULE, inform your doctor, if you are taking any of the following medicine:
Overdosage:
If you or anyone else accidentally takes too much of AFOGATRAN 150MG CAPSULE, consult your doctor immediately or visit the nearby hospital.
| Drug | : | Dabigatran etexilate |
| Pharmacological Category | : | Anticoagulants |
| Therapeutic Indication | : | Prevent stroke, systemic embolism and reduction of vascular mortality in adult patients with atrial fibrillation, Venous thromboembolic events in patients who have undergone orthopaedic surgery, Blood clot disorders |
| Dosage Forms | : | Capsule, Tablet |
What AFOGATRAN 150MG CAPSULE is used for?
AFOGATRAN 150MG CAPSULE is used to prevent stroke, systemic embolism and reduction of vascular mortality in adult patients with atrial fibrillation and venous thromboembolic events in patients who have undergone orthopaedic surgery.
How should AFOGATRAN 150MG CAPSULE be taken?
Take AFOGATRAN 150MG CAPSULE as advised by your physician. Swallow AFOGATRAN 150MG CAPSULE with a glass of water and do not chew or crush the medicine. Your doctor will decide the correct dose and duration for you depending upon your age, body weight and disease condition.
What are the side effects of AFOGATRAN 150MG CAPSULE?
The most common symptoms of taking AFOGATRAN 150MG CAPSULE are stomachache, indigestion , frequent loose or liquid bowel movements and nausea. Consult your doctor if any of these above side effects gets worse.
What happens if you stop taking AFOGATRAN 150MG CAPSULE?
Do not stop taking AFOGATRAN 150MG CAPSULE without talking to your doctor first, because the risk of developing a blood clot could be higher if you stop treatment too early. Consult your doctor if you have any queries regarding stopping the medicine.
Is AFOGATRAN 150MG CAPSULE safe to use in children?
AFOGATRAN 150MG CAPSULE is recommended for use in children and adolescents (from 8 to 18 years of age) to treat and reduce the risk of recurrence of blood clot disorder. Your doctor will prescribe the right dose depends on your child’s age, body weight and disease condition. Consult your doctor before taking AFOGATRAN 150MG CAPSULE.
1. KD. Tripathi. Drugs Affecting Coagulation, Bleeding and Thrombosis. Seventh edition. 2013. Page – 623.
2. Boehringer Ingelheim. Safety of Dabigatran Etexilate in Blood Clot Prevention in Children. NIH U.S. National Library of Medicine ClinicalTrials.gov. [Revised in June 2020] [Accessed on 30th May 2022] https://clinicaltrials.gov/ct2/show/NCT02197416
3. Eline A Dubois and Adam F Cohen. Dabigatran etexilate. NIH National Library of Medicine, National center for biotechnology information. PMC PubMed Central. July 2010. [Accessed on 30th May 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2909802/
4. Teerapat Nantsupawat, Suthipong Soontrapa, Nopakoon Nantsupawat, David Sotello, Saranapoom Klomjit, Selcuk Adabag and Alejandro Perez-Verdia. Risk factors and prevention of dabigatran-related gastrointestinal bleeding in patients with atrial fibrillation. NIH National Library of Medicine, National center for biotechnology information. PMC PubMed Central. February 2018. [Accessed on 30th May 2022] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828263/
5. Boehringer Ingelheim Pharmaceuticals, Inc. PRADAXA. [Revised in June 2021] [Accessed on 30th May 2022] https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf
6. Boehringer Ingelheim International GmbH. Electronic medicines compendium (EMC). [Revised in January 2021] [Accessed on 30th May 2022] https://www.medicines.org.uk/emc/files/pil.6228.pdf
7. Boehringer Ingelheim International GmbH. Electronic medicines compendium (EMC). [Revised in January 2021] [Accessed on 30th May 2022] https://www.medicines.org.uk/emc/files/pil.6229.pdf
8. Boehringer Ingelheim International GmbH. Electronic medicines compendium (EMC). [Revised in January 2021] [Accessed on 30th May 2022] https://www.medicines.org.uk/emc/files/pil.4703.pdf
9. Boehringer Ingelheim Pharmaceuticals, Inc. U.S. Food & Drug Administration (EMC). [Revised in November 2015] [Accessed on 30th May 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s028lbl.pdf
Written By Dr. Janet.C, Pharm.D
Last updated on 10 Nov 2022 | 09:54 AM(IST)